Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 101

Results For "RET"

1729 News Found

AiMeD expresses dismay over FICCI’s ‘Un-Make in India’ drive
News | July 29, 2023

AiMeD expresses dismay over FICCI’s ‘Un-Make in India’ drive

Unfortunate to see PM’s ‘Make in India’ dream being bulldozed


Need to strengthen food safety scientific standards: NITI Aayog
Policy | July 24, 2023

Need to strengthen food safety scientific standards: NITI Aayog

There is a pressing need for continuous improvement and innovation in food safety systems to keep pace with emerging food trends and habits


India brings traditional medicine at the forefront of India’s G20 presidency discourse: Amitabh Kant
News | July 24, 2023

India brings traditional medicine at the forefront of India’s G20 presidency discourse: Amitabh Kant

Traditional medicine effectively highlighted in all health and engagement working groups meeting and Ministry of Ayush acknowledges these efforts


M&A activity of pharma CMOs will continue despite challenging borrowing environment, says GlobalData
News | July 20, 2023

M&A activity of pharma CMOs will continue despite challenging borrowing environment, says GlobalData

CMOs showed an increasing reluctance to take on debt in 2022


Wockhardt Hospitals, Mira Road launches training program for family physician
News | July 20, 2023

Wockhardt Hospitals, Mira Road launches training program for family physician

To equip them with the latest knowledge and skills to handle patients coming to them in a better way


Helping Hand Foundation launches screening for glaucoma in Hyderabad
Healthcare | July 19, 2023

Helping Hand Foundation launches screening for glaucoma in Hyderabad

First of its kind screening for Glaucoma at grass root level over 10k screened already


Sumitomo Pharma America launches as new combined organization
News | July 11, 2023

Sumitomo Pharma America launches as new combined organization

SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets